close

NSCLC EGFR Mutation Test


EGFR testing with liquid biopsy

Read More

Introduction


■EGFR mutation in NSCLC


Activating mutations in the gene encoding EGFR occur primarily in non-
small cell lung cancer (NSCLC), and result in constitutive activation of
the kinase activity of the EGFR protein, thereby contributing to the
oncogenic process. The prevalence of these mutations in unselected
cases of NSCLC is approximately 30%-40% of Asian populations. Several
reports indicate that EGFR mutations can be detected in plasma or
serum of NSCLC patients.



■ FDA approves first liquid biopsy test for EGFR mutations in NSCLC


The cobas® EGFR Mutation Test v2 companion diagnostic looks for small
fragments of circulating tumour DNA (ctDNA) in the patient's
bloodstream, which allows a diagnosis just using a blood sample. This
enables patients to avoid an invasive tissue biopsy when their lung
cancer progresses after first-line treatment with an EGFR-TKI.



The advantages of liquid biopsy


■Non-invasive


Only blood drawn, suitable for too unhealthy for tissue biopsy.


■Heterogeneity


Liquid biopsy techniques capable of capturing tumor heterogeneity and the molecular changes cancer cells undergo when they are exposed to
therapy are needed.


■Disease monitoring


There are rapid increases in ctDNA levels with disease progression and
corresponding declines in levels after successful treatment with
pharmacologic therapy or resective surgery.

Indication


NSCLC pateints

Description


Detect 42 mutations in EGFR exons 18, 19, 20, 21

Patient Story


How It Works


Step1. Consulting with physician to understand the test content


Step2. Go hospitals to collect specimen and fill out the consent form


Step3. Send specimen to SOFIVA lab


Step4. DNA extraction and analysis


Step5. The report will be provided in 5 business days



*You should consult with your physician.

Others


FDA approves first liquid biopsy test for EGFR mutations in NSCLC